Body mass index and impaired fasting blood glucose as predictive factor of time to progression (TTP) in cetuximab-based colorectal cancer treatment

Francesco Pantano; Francesco Maria Guida; Caterina Vivaldi; Bruno Vincenzi; Enrique Grande; Mercedes Rodriguez Garrote; Michele Caraglia; Nicola Silvestris; Enrico Vasile; Gianluca Masi; Alfredo Falcone; Giuseppe Tonini; Daniele Santini

doi:10.4161/cbt.24346

Body mass index and impaired fasting blood glucose as predictive factor of time to progression (TTP) in cetuximab-based colorectal cancer treatment

Francesco Pantano, Francesco Maria Guida, Caterina Vivaldi, Bruno Vincenzi, Enrique Grande, Mercedes Rodriguez Garrote, Michele Caraglia, Nicola Silvestris, Enrico Vasile, Gianluca Masi, Alfredo Falcone, Giuseppe Tonini, Daniele Santini

IRCCS Giovanni Paolo II

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	467-468
Number of pages	2
Journal	Cancer Biology and Therapy
Volume	14
Issue number	6
DOIs	https://doi.org/10.4161/cbt.24346
Publication status	Published - 2013

Keywords

Anti-EFGR
Body mass index
Cancer
Cetuximab
Colorectal cancer
FBG
TTP

ASJC Scopus subject areas

Cancer Research
Oncology
Molecular Medicine
Pharmacology
Medicine(all)

Access to Document

10.4161/cbt.24346

Cite this

Pantano, F., Guida, F. M., Vivaldi, C., Vincenzi, B., Grande, E., Garrote, M. R., Caraglia, M., Silvestris, N., Vasile, E., Masi, G., Falcone, A., Tonini, G., & Santini, D. (2013). Body mass index and impaired fasting blood glucose as predictive factor of time to progression (TTP) in cetuximab-based colorectal cancer treatment. Cancer Biology and Therapy, 14(6), 467-468. https://doi.org/10.4161/cbt.24346

Body mass index and impaired fasting blood glucose as predictive factor of time to progression (TTP) in cetuximab-based colorectal cancer treatment. / Pantano, Francesco; Guida, Francesco Maria; Vivaldi, Caterina; Vincenzi, Bruno; Grande, Enrique; Garrote, Mercedes Rodriguez; Caraglia, Michele; Silvestris, Nicola; Vasile, Enrico; Masi, Gianluca; Falcone, Alfredo; Tonini, Giuseppe; Santini, Daniele.

In: Cancer Biology and Therapy, Vol. 14, No. 6, 2013, p. 467-468.

Research output: Contribution to journal › Article › peer-review

Pantano, F, Guida, FM, Vivaldi, C, Vincenzi, B, Grande, E, Garrote, MR, Caraglia, M, Silvestris, N, Vasile, E, Masi, G, Falcone, A, Tonini, G & Santini, D 2013, 'Body mass index and impaired fasting blood glucose as predictive factor of time to progression (TTP) in cetuximab-based colorectal cancer treatment', Cancer Biology and Therapy, vol. 14, no. 6, pp. 467-468. https://doi.org/10.4161/cbt.24346

Pantano, Francesco ; Guida, Francesco Maria ; Vivaldi, Caterina ; Vincenzi, Bruno ; Grande, Enrique ; Garrote, Mercedes Rodriguez ; Caraglia, Michele ; Silvestris, Nicola ; Vasile, Enrico ; Masi, Gianluca ; Falcone, Alfredo ; Tonini, Giuseppe ; Santini, Daniele. / Body mass index and impaired fasting blood glucose as predictive factor of time to progression (TTP) in cetuximab-based colorectal cancer treatment. In: Cancer Biology and Therapy. 2013 ; Vol. 14, No. 6. pp. 467-468.

@article{9705a31d67f242a3b5246744796f000f,

title = "Body mass index and impaired fasting blood glucose as predictive factor of time to progression (TTP) in cetuximab-based colorectal cancer treatment",

keywords = "Anti-EFGR, Body mass index, Cancer, Cetuximab, Colorectal cancer, FBG, TTP",

author = "Francesco Pantano and Guida, {Francesco Maria} and Caterina Vivaldi and Bruno Vincenzi and Enrique Grande and Garrote, {Mercedes Rodriguez} and Michele Caraglia and Nicola Silvestris and Enrico Vasile and Gianluca Masi and Alfredo Falcone and Giuseppe Tonini and Daniele Santini",

year = "2013",

doi = "10.4161/cbt.24346",

language = "English",

volume = "14",

pages = "467--468",

journal = "Cancer Biology and Therapy",

issn = "1538-4047",

publisher = "Landes Bioscience",

number = "6",

}

TY - JOUR

T1 - Body mass index and impaired fasting blood glucose as predictive factor of time to progression (TTP) in cetuximab-based colorectal cancer treatment

AU - Pantano, Francesco

AU - Guida, Francesco Maria

AU - Vivaldi, Caterina

AU - Vincenzi, Bruno

AU - Grande, Enrique

AU - Garrote, Mercedes Rodriguez

AU - Caraglia, Michele

AU - Silvestris, Nicola

AU - Vasile, Enrico

AU - Masi, Gianluca

AU - Falcone, Alfredo

AU - Tonini, Giuseppe

AU - Santini, Daniele

PY - 2013

Y1 - 2013

KW - Anti-EFGR

KW - Body mass index

KW - Cancer

KW - Cetuximab

KW - Colorectal cancer

KW - FBG

KW - TTP

UR - http://www.scopus.com/inward/record.url?scp=84879159273&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879159273&partnerID=8YFLogxK

U2 - 10.4161/cbt.24346

DO - 10.4161/cbt.24346

M3 - Article

C2 - 23760487

AN - SCOPUS:84879159273

VL - 14

SP - 467

EP - 468

JO - Cancer Biology and Therapy

JF - Cancer Biology and Therapy

SN - 1538-4047

IS - 6

ER -

Body mass index and impaired fasting blood glucose as predictive factor of time to progression (TTP) in cetuximab-based colorectal cancer treatment

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this